Swollen lymph nodes may not be clinical manifestations of chronic myeloid leukemia: case report and revision of literature.

abstract：:The topoisomerase I inhibitor topotecan is the only single-agent therapy approved for the treatment of recurrent small cell lung cancer (SCLC). Many patients with recurrent SCLC may be predisposed to treatment-related adverse events because of the presence of comorbidities such as advanced age, renal impairment, or ex...

journal_title：Therapeutics and clinical risk management

authors： Garst J

更新日期：2007-12-01 00:00:00

abstract：:Preterm birth is the major cause of perinatal morbidity and mortality in the developed world, and spontaneous preterm labor is the commonest cause of preterm birth. Interventions to treat women in spontaneous preterm labor have not reduced the incidence of preterm births but this may be due to increased risk factors, ...

journal_title：Therapeutics and clinical risk management

authors： Sanu O,Lamont RF

更新日期：2010-04-26 00:00:00

abstract：BACKGROUND:Hypertension is a highly prevalent risk factor for cardiovascular disease in patients with type 1 diabetes mellitus. Elevated blood pressure (BP) promotes the development and progression of microvascular complications, eg, nephropathy and retinopathy. The purpose of this study was to identify and detect earl...

journal_title：Therapeutics and clinical risk management

authors： Shalaby NM,Shalaby NM

更新日期：2015-10-05 00:00:00

abstract：OBJECTIVE:To determine the influence of various patient-specific factors, use of concomitant medications, and weekly vitamin K intake on total weekly warfarin maintenance dose (TWD). METHODS:Information collected, via retrospective chart review, included TWD, general demographics, vitamin K consumption, target INR ran...

journal_title：Therapeutics and clinical risk management

authors： Whitley HP,Fermo JD,Chumney EC,Brzezinski WA

更新日期：2007-06-01 00:00:00

abstract：:Uncontrolled asthma continues to be a problem for many patients with moderate-to-severe allergic asthma. Dupilumab, which blocks the receptors for interleukin-4 and interleukin-13, has been effective in reducing asthma exacerbations, improving forced expiratory volume in one second (FEV1), and reducing oral corticoste...

journal_title：Therapeutics and clinical risk management

authors： Brooks GD

更新日期：2020-03-04 00:00:00

abstract：BACKGROUND:The aim of this open-label, randomized, parallel-group pilot study was to evaluate the efficacy of cefditoren pivoxil and levofloxacin in terms of speed of reduction in inflammatory parameters, clinical recovery, and microbiological eradication. METHODS:Forty eligible patients with acute exacerbation of chr...

journal_title：Therapeutics and clinical risk management

authors： Blasi F,Tarsia P,Mantero M,Morlacchi LC,Piffer F

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:The irradiation of head and neck cancer (HNC) often causes damage to the salivary glands. The resulting salivary gland hypofunction and xerostomia seriously reduce the patient's quality of life. PURPOSE:To analyze the literature of actual management strategies for radiation-induced hypofunction and xerostom...

journal_title：Therapeutics and clinical risk management

authors： Pinna R,Campus G,Cumbo E,Mura I,Milia E

更新日期：2015-02-04 00:00:00

abstract：:Psoriasis is a common, chronic, inflammatory skin disease that can have a significant impact on the quality of life of those who are afflicted. Recent advances in the understanding of the pathophysiology of psoriasis have led to the development of new, genetically engineered, targeted therapies for this disease. Among...

journal_title：Therapeutics and clinical risk management

authors： Alwawi EA,Mehlis SL,Gordon KB

更新日期：2008-04-01 00:00:00

abstract：:The introduction of TNFα blockers has revolutionized the treatment of ankylosing spondylitis (AS). The objectives of this review are to summarize the most up-to-date data on long-term efficacy and safety of infliximab in AS, with special emphasis on axial and extra-articular disease, predictors of response, and radiol...

journal_title：Therapeutics and clinical risk management

authors： Elalouf O,Elkayam O

更新日期：2015-11-19 00:00:00

abstract：:Behçet's disease is an autoinflammatory vasculitis of unknown origin characterized by recurrent oral and genital ulcers, uveitis, arthritis and skin lesions. Additionally, involvement of the gastrointestinal tract, central nervous system and large vessels may occur. The disease is prevalent in countries along the anci...

journal_title：Therapeutics and clinical risk management

authors： van Daele PL,Kappen JH,van Hagen PM,van Laar JA

更新日期：2009-04-01 00:00:00

abstract：AIM:To evaluate the efficacy of glycopyrrolate oral solution (1 mg/5 mL) in managing problem drooling associated with cerebral palsy and other neurologic conditions. METHOD:Thirty-eight patients aged 3-23 years weighing at least 27 lb (12.2 kg) with severe drooling (clothing damp 5-7 days/week) were randomized to glyc...

journal_title：Therapeutics and clinical risk management

authors： Zeller RS,Lee HM,Cavanaugh PF,Davidson J

更新日期：2012-01-01 00:00:00

abstract：AIM:To compare the long-term survival outcomes of radiofrequency ablation and liver resection for single very early/early stage hepatocellular carcinoma (HCC). METHODS:The Cochrane Library (Issue 3, 2015), Embase (1974 to March 15, 2015), PubMed (1950 to March 15, 2015), Web of Science (1900 to March 15, 2015), and Ch...

journal_title：Therapeutics and clinical risk management

authors： He ZX,Xiang P,Gong JP,Cheng NS,Zhang W

更新日期：2016-02-23 00:00:00

abstract：:The treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) positively changed since the introduction of anti-TNFα drugs. These treatments were shown to reduce the symptoms and signs of the diseases and improve the quality of life. However, a variable percentage of patients do not respond to anti-TNFα o...

journal_title：Therapeutics and clinical risk management

authors： Lubrano E,Perrotta FM

更新日期：2016-10-21 00:00:00

abstract：BACKGROUND:Despite the well recognized protective effect of cruciferous vegetables against various cancers, including human colorectal cancers, little is known about how this effect is conferred. It is thought that some phytochemicals found only in these vegetables confer the protection. These compounds include the glu...

journal_title：Therapeutics and clinical risk management

authors： McGrath DR,Frydoonfar H,Hunt JJ,Dunkley CJ,Spigelman AD

更新日期：2010-05-25 00:00:00

abstract：BACKGROUND:Internationally, there is a remarkable achievement in the areas of drug discovery, drug design, and clinical trials. New and efficient drug formulation techniques are widely available which have led to success in treatment of several diseases. Despite these achievements, large number of patients continue to ...

journal_title：Therapeutics and clinical risk management

authors： Abubakar AR,Ismail S,Rahman NI,Haque M

更新日期：2015-06-30 00:00:00

abstract：:A utilization study was performed in a 2200-bed tertiary care teaching hospital. Data mining was performed on all nasogastric medication prescriptions for patients hospitalized in 2011. Nurses were interviewed by questionnaire. A PDCA (Plan-Do-Check-Act) cycle was used for continuous quality improvement. The proportio...

journal_title：Therapeutics and clinical risk management

authors： Zhu LL,Xu LC,Wang HQ,Jin JF,Wang HF,Zhou Q

更新日期：2012-01-01 00:00:00

abstract：:Hepatoid adenocarcinoma of the stomach (HAS) is a rare subgroup of gastric cancer (GC). Morphologically, this tumor exhibits both adenocarcinomatous and hepatocellular differentiation, and most tumors show immunohistochemical staining for alpha-fetoprotein (AFP) or elevated AFP serum levels. The diagnosis of HAS is fr...

journal_title：Therapeutics and clinical risk management

authors： Søreide JA

更新日期：2019-12-23 00:00:00

abstract：:Opioid analgesics are essential in the treatment of moderate to severe cancer-related pain. Opioids are also recognized as important in the management of other severe, persistent refractory painful conditions, such as sickle cell disease and arthritis. In the clinical practice of pain management, stable opioid dosing ...

journal_title：Therapeutics and clinical risk management

authors： Weinstein SM

更新日期：2009-02-01 00:00:00

abstract：:Hyperphosphatemia is an inevitable consequence of end stage chronic kidney disease and is present in the majority of dialysis patients. Recent observational data has associated hyperphosphatemia with increased cardiovascular mortality among dialysis patients. Dietary restriction of phosphate and current dialysis presc...

journal_title：Therapeutics and clinical risk management

authors： Mohammed IA,Hutchison AJ

更新日期：2008-10-01 00:00:00

abstract：:Cariprazine is a recently developed antipsychotic drug with a partial agonism for the D2 and D3 receptors. It shows a tenfold greater affinity for the D3 receptor. In clinical trials, its therapeutic effect has been tested in patients with an acute exacerbation of schizophrenia and in patients with acute mania in bipo...

journal_title：Therapeutics and clinical risk management

authors： Werner FM,Coveñas R

更新日期：2015-11-02 00:00:00

abstract：:Purpose: This study aimed to assess the effect of intravenous dexmedetomidine (DEX) on sevoflurane EC50 for supraglottic airway device (SAD) insertion in spontaneously breathing morbidly obese patients. Patients and methods: Thirty-eight morbidly obese patients with a body mass index 40-57 kg/m2 who were scheduled for...

journal_title：Therapeutics and clinical risk management

authors： Wan L,Shao LJ,Liu Y,Wang HX,Xue FS,Tian M

更新日期：2019-05-03 00:00:00

abstract：Background:Liver cirrhosis is an uncommon but not rare side effect of amiodarone-induced hepatotoxicity. Patients with hepatitis B virus and hepatitis C virus infections are at a high risk for developing liver cirrhosis. However, the relationship between this treatment and risk of liver cirrhosis in high-risk chronic h...

journal_title：Therapeutics and clinical risk management

authors： Huang CH,Lai YY,Kuo YJ,Yang SC,Chang YJ,Chang KK,Chen WK

更新日期：2019-01-10 00:00:00

abstract：Background:The aim of this study was to evaluate the efficacy of induction chemotherapy (IC) in nasopharyngeal carcinoma (NPC) patients with moderate-risk treated with intensity-modulated radiotherapy (IMRT). Methods:We retrospectively assessed 506 patients with T1-2N1M0 or T3-4N0-1M0 NPC (according to the 2010 UICC/A...

journal_title：Therapeutics and clinical risk management

authors： Su Z,Zou GR,Tang J,Li XY,Xie FY

更新日期：2020-03-26 00:00:00

abstract：Background:Treatment-related problems (TRPs) may pose risks for patients if unaddressed. With the increased complexity of health care, it is important to target pharmacists' efforts to patients that are at high risk for TRPs. Objectives:The present study aimed to identify medications most commonly associated with TRPs...

journal_title：Therapeutics and clinical risk management

authors： Al-Taani GM,Al-Azzam SI,Alzoubi KH,Aldeyab MA

更新日期：2018-11-16 00:00:00

abstract：:Treatment of HIV-1 infection has produced dramatic success for many patients. Nevertheless, viral resistance continues to limit the efficacy of currently available agents in many patients. The CCR5 antagonists are a new class of antiretroviral agents that target a necessary coreceptor for viral entry of many strains o...

journal_title：Therapeutics and clinical risk management

authors： Schlecht HP,Schellhorn S,Dezube BJ,Jacobson JM

更新日期：2008-04-01 00:00:00

abstract：Background:Anesthesia and surgery may deteriorate liver function in patients with elevated liver enzyme levels; therefore, in these patients, choosing anesthetics with less hepatotoxicity is important. Methods:This retrospective study investigated the effect of total intravenous anesthesia (TIVA) versus inhalation ane...

journal_title：Therapeutics and clinical risk management

authors： Oh SK,Lim BG,Kim YS,Kim SS

更新日期：2020-04-05 00:00:00

abstract：:Vorapaxar (ZONTIVITY™, formerly known as SCH 530348) is a specific, orally active antagonist of the protease-activated receptor-1 (PAR-1) on platelets. It inhibits thrombin-induced platelet activation by binding to the ectodomain of PAR-1. After animal studies and Phase II studies showed that vorapaxar sufficiently in...

journal_title：Therapeutics and clinical risk management

authors： Diehl P,Bode C,Duerschmied D

更新日期：2015-08-03 00:00:00

abstract：:Pemphigus vulgaris (PV) is a life-threatening disease belonging to the pemphigus group of autoimmune intra-epidermal bullous diseases of the skin and mucosae. The therapeutic management of PV remains challenging and, in some cases, conventional therapy is not adequate to induce clinical remission. The cornerstone of P...

journal_title：Therapeutics and clinical risk management

authors： Kridin K

更新日期：2018-04-27 00:00:00

abstract：:Cerebral palsy (CP) is the main cause of physical disability in childhood and is an important health issue that has a strong socioeconomic impact. There is no effective treatment for CP and therapeutic approaches report only partial benefits for affected people. In this study we assessed the effects of growth hormone ...

journal_title：Therapeutics and clinical risk management

authors： Devesa J,Alonso B,Casteleiro N,Couto P,Castañón B,Zas E,Reimunde P

更新日期：2011-01-01 00:00:00

abstract：Background:Cardiovascular diseases (CVD) combined with Type 2 diabetes mellitus (T2DM) frequently occurred. In this study, we aimed at exploring the prognostic significance of blood neutrophil-lymphocyte ratio (NLR) in these types of patients. Patients and Methods:Between June 30, 2010 and August 30, 2017, 1454 pati...

journal_title：Therapeutics and clinical risk management

authors： Qiao S,Gao W,Guo S

更新日期：2020-05-19 00:00:00